What is the appropriate approach to treating women with incurable cervical cancer?

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 11, Issue 3, 2013, Pages 348-355

  Ramondetta, Lois ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b HARRIS COUNTY HOSPITAL DISTRICT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBOPLATIN; PACLITAXEL;

ADULT; ANXIETY; CACHEXIA; CANCER RECURRENCE; CANCER THERAPY; CASE REPORT; CAUSE OF DEATH; CHRONIC PAIN; COMPUTER ASSISTED TOMOGRAPHY; DOCTOR PATIENT RELATION; FATIGUE; FEMALE; HUMAN; LIFE EXPECTANCY; MEDICAL DECISION MAKING; NUCLEAR MAGNETIC RESONANCE IMAGING; PERCUTANEOUS NEPHROSTOMY; PHYSICAL EXAMINATION; PSYCHOSOCIAL ADJUSTMENT TO ILLNESS SCALE; QUALITY OF LIFE; REVIEW; SOCIAL ASPECT; TREATMENT PLANNING; UTERINE CERVIX CANCER; VAGINA DISCHARGE;

EID: 84875905174     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2013.0044     Document Type: Review

References (78)

1. Monk BJ, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinatins in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2009;27:4649-4655.
2. World Health Organization. WHO Definition of Palliative Care. Available at: http://www.who.int/entity/cancer/palliative/definition/en/. Accessed February 12, 2013.
3. Earle CC, Neville BA, Landrum MB, et al. Trends in the aggressiveness of cancer care near the end of life. J Clin Oncol 2004;22:315-321.
4. Barbera L, Elit L, Krzyzanowska M, et al. End of life care for women with gynecologic cancers. Gynecol Oncol 2010;118:196-201.
5. Glare P, Virik K, Jones M, et al. A systematic review of physicians' survival predictions in terminally ill cancer patients. BMJ 2003;327:195-198.
6. Gurmankin AD, Baron J, Hershey JC, Ubel PA. The role of physicians' recommendations in medical treatment decisions. Med Decis Making 2002;22:262-271.
7. Ramondetta LM, Brown A, Richardson G, et al. Religious and spiritual beliefs of gynecologic oncologists may influence medical decision making. Int J Gynecol Cancer 2011;21:573-581.
8. Yellen SB, Cella DF. Someone to live for: social well-being, parenthood status, and decision-making in oncology. J Clin Oncol 1995;13:1255-1264.
9. Haggerty J, Tudiver F, Brown JB, et al. Patients' anxiety and expectations: how they influence family physicians' decisions to order cancer screening tests. Can Fam Physician 2005;51:1658-1659.
10. Mack JW, Smith TJ. Reasons why physicians do not have discussions about poor prognosis, why it matters, and what can be improved. J Clin Oncol 2012;30:2715-2717.
11. Ferrandina G, Mantegna G, Petrillo M, et al. Quality of life and emotional distress in early stage and locally advanced cervical cancer patients: a prospective, longitudinal study. Gynecol Oncol 2012;124:389-394.
12. Klopp AH, Eifel PJ. Biological predictors of cervical cancer response to radiation therapy. Semin Radiat Oncol 2012;22:143-150.
13. Chase DM, Huang HQ, Wenzel L, et al. Quality of life and survival in advanced cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2012;125:315-319.
14. Sanchez-Munoz A, Perez-Ruiz E, Saez MI, et al. Limited impact of palliative chemotherapy on survival in advanced solid tumours in patients with poor performance status. Clin Transl Oncol 2011;13:426-429.
15. Temel JS, Greer JA, Muzikansky A, et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010;363:733-742.
16. Connor SR, Pyenson B, Fitch K, et al. Comparing hospice and nonhospice patient survival among patients who die within a three-year window. J Pain Symptom Manage 2007;33:238-246.
17. Smith TJ, Temin S, Alesi ER, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 2012;30:880-887.
18. Jacobsen PB, Donovan KA, Trask PC, et al. Screening for psychologic distress in ambulatory cancer patients. Cancer 2005;103:1494-1502.
19. Ramondetta LM, Fields MM, Fisch MJ. Supportive care for women with cervical cancer. In: Jinghram A, Levenbach C, eds. Cervical Cancer: State of the Art. London, United Kingdom: Remecia Medical Education and Publication; in press.
20. Beesley V, Janda M, Eakin E, et al. Lymphedema after gynecological cancer treatment: prevalence, correlates, and supportive care needs. Cancer 2007;109:2607-2614.
21. Burke C. Rectovaginal fistulas. Clin J Oncol Nurs 2005;9:295-297.
22. Leissner J, Black P, Filipas D, et al. Vaginal reconstruction using the bladder and/or rectal walls in patients with radiation-induced fistulas. Gynecol Oncol 2000;78:356-360.
23. Chamberlain RS, Kaufman HL, Danforth DN. Enterocutaneous fistula in cancer patients: etiology, management, outcome, and impact on further treatment. Am Surg 1998;64:1204-1211.
24. Von Gruenigen VE, Coleman RL, Li AJ, et al. Bacteriology and treatment of malodorous lower reproductive tract in gynecologic cancer patients. Obstet Gynecol 2000;96:23-27.
25. Prue G, Rankin J, Allen J, et al. Cancer-related fatigue: a critical appraisal. Eur J Cancer 2006;42:846-863.
26. Wagner LI, Cella D. Fatigue and cancer: causes, prevalence and treatment approaches. Br J Cancer 2004;91:822-828.
27. Levy MH, Adolph MD, Back A, et al. NCCN Clinical Practice Guidelines in Oncology for Palliative Care. Version 2.2012. Available at NCCN.org. Accessed February 26, 2013.
28. Vistad I, Cvancarova M, Kristensen GB, Fossa SD. A study of chronic pelvic pain after radiotherapy in survivors of locally advanced cervical cancer. J Cancer Surviv 2011;5:208-216.
29. Long HJ, Bundy BN, Grendys. EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol 2005;23:4626-4633.
30. Cella D, Huang HQ, Monk BJ, et al. Health-related quality of life outcomes associated with four cisplatin-based doublet chemotherapy regimens for stage IVB recurrent or persistent cervical cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2010;119:531-537.
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
32. Mackay HJ, Tinker A, Winquist E, et al. A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184. Gynecol Oncol 2010;116:163-167.
33. Kurtz JE, Hardy-Bessard AC, Deslandres M, et al. Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: a phase II GINECO trial. Gynecol Oncol 2009;113:16-20.
34. von Gruenigen VE, Daly BJ. Futility: clinical decisions at the end-of-life in women with ovarian cancer. Gynecol Oncol 2005;97:638-644.
35. Monk BJ, Sill MW, Burger RA, et al. Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: a gynecologic oncology group study. J Clin Oncol 2009;27:1069-1074.
36. Tan S, de Vries EG, van der Zee AG, de Jong S. Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets 2012;12:170-184.
37. Monk BJ, Willmott LJ, Sumner DA. Anti-angiogenesis agents in metastatic or recurrent cervical cancer. Gynecol Oncol 2010;116:181-186.
38. Bonifazi M, Rossi M, Moja L, et al. Bevacizumab in clinical practice: prescribing appropriateness relative to national indications and safety. Oncologist 2012;17:117-124.
39. Santin AD, Sill MW, McMeekin DS, et al. Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:495-500.
40. Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Ann Oncol 2010;21:61-66.
41. Schilder RJ, Sill MW, Lee YC, Mannel R. A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Int J Gynecol Cancer 2009;19:929-933.
42. Peele PB, Siminoff LA, Xu Y, Ravdin PM. Decreased use of adjuvant breast cancer therapy in a randomized controlled trial of a decision aid with individualized risk information. Med Decis Making 2005;25:301-307.
43. Smith TJ, Lindsay AD, Virago EA, et al. A pilot trial of decision aids to give truthful prognostic and treatment information to chemotherapy patients with advanced cancer. J Support Oncol 2011;9:79-86.
44. Shiromizu K, Kasamatsu T, Honma T, et al. Clinicopathological study of recurrent uterine cervical squamous-cell carcinoma. J Obstet Gynaecol Res 1999;25:395-399.
45. Moore DH, Tian C, Monk BJ, et al. Prognostic factors for response to cisplatin-based chemotherapy in advanced cervical carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol 2010;116:44-49.
46. ASCO. Clinical Tools and Resources for Lung Cancer. Available at: http://www.asco.org/ascov2/Practice+&+Guidelines/Guidelines/ clinical+Tools+and+Resources/Lung+Cancer. Accessed February 12, 2013.
47. Weeks JC, Catalano PJ, Cronin A, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med 2012;367:1616-1625.
48. Back AL, Arnold RM, Quill TE. Hope for the best, and prepare for the worst. Ann Intern Med 2003;138:439-443.
49. De Punzio C, Salvestroni C, Guazzelli G, et al. Stess and cervical dysplasia. Eur J Gynaecol Oncol 1998;XIX:287-290.
50. Coker AL, Bond S, Madeleine MM, et al. Psychosocial stress and cervical neoplasia risk. Psychosom Med 2003;65:644-651.
51. Reiche EM, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617-625.
52. Antoni MH, Lutgendorf SK, Cole SW, et al. The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 2006;6:240-248.
53. Thaker PH, Sood AK. Neuroendocrine influences on cancer biology. Semin Cancer Biol 2008;18:164-170.
54. Thaker PH, Han LY, Kamat AA, et al. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006;12:939-944.
55. Wong HP, Yu L, Lam EK, et al. Nicotine promotes colon tumor growth and angiogenesis through beta-adrenergic activation. Toxicol Sci 2007;97:279-287.
56. Al-Wadei HA, Ullah MF, Al-Wadei MH. Intercepting neoplastic progression in lung malignancies via the beta adrenergic (beta-AR) pathway: implications for anti-cancer drug targets. Pharmacol Res 2012;66:33-40.
57. Frumovitz M, Sun CC, Schover LR, et al. Quality of life and sexual functioning in cervical cancer survivors. J Clin Oncol 2005;23:7428-7436.
58. Wenzel L, DeAlba I, Habbal R, et al. Quality of life in long-term cervical cancer survivors. Gynecol Oncol 2005;97:310-317.
59. Wenzel L, Dogan-Ates A, Habbal R, et al. Defining and measuring reproductive concerns of female cancer survivors. J Natl Cancer Inst Monogr 2005:94-98.
60. Basen-Engquist K, Bodurka-Bevers D, Fitzgerald MA, et al. Reliability and validity of the functional assessment of cancer therapy-ovarian. J Clin Oncol 2001;19:1809-1817.
61. Pereira DB, Antoni MH, Fletcher MA, O'Sullivan MJ. Cognitive behavioral stress management (CBSM) effects on regression of cervical dysplasia among HIV+ women [abstract]. Psychosom Med 2005;67:Abstract 1152.
62. Nelson EL, Wenzel LB, Osann K, et al. Stress, immunity, and cervical cancer: biobehavioral outcomes of a randomized clinical trial. Clin Can Res 2008;14:2111-2118.
63. Cohen L, Parker PA, Vence L, et al. Presurgical stress management improves postoperative immune function in men with prostate cancer undergoing radical prostatectomy. Psychosom Med 2011;73:218-225.
64. Lutgendorf SK, Mullen-Houser E, Russell D, et al. Preservation of immune function in cervical cancer patients during chemoradiation using a novel integrative approach. Brain Behav Immun 2010;24:1231-1240.
65. Diaz ES, Karlan BY, Li AJ, et al. Impact of beta blockers on epithelial ovarian cancer survival. Gynecol Oncol 2012;127:375-378.
66. Powe DG, Voss MJ, Zanker KS, et al. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010;1:628-638.
67. Melhem-Berrandt A, Chavez-Macgregor M, Lei X, et al. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011;29:2645-2652.
68. De Giorgi V, Grazzini M, Gandini S, et al. Treatment with β-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med 2011;171:779-781.
69. Badino GR, Novelli A, Girardi C, Di Carlo F. Evidence for functional beta-adrenoceptor subtypes in CG-5 breast cancer cell. Pharmacol Res 1996;33:255-260.
70. Liu X, Wu WK, Yu L, et al. Epinephrine stimulates esophageal squamous-cell carcinoma cell proliferation via beta-adrenoceptor-dependent transactivation of extracellular signal-regulated kinase/cyclooxygenase-2 pathway. J Cell Biochem 2008;105:53-60.
71. Sood AK, Bhatty R, Kamat AA, et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006;12:369-375.
72. Palm D, Lang K, Niggemann B, et al. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by beta-blockers. Int J Cancer 2006;118:2744-2749.
73. Madden KS, Szpunar MJ, Brown EB. β-Adrenergic receptors (B-AR) regulate VEGF and IL-6 production by divergent pathways in high B-AR-expressing breast cancer cell lines. Breast Cancer Res Treat 2011;130:747-758.
74. Ramondetta LM, Kang Y, Hu W, et al. The clinical significance of beta adrenergic receptor expression in cervical cancer tissue. Presented at the 44th Annual Meeting Annual Society of Gynecologic Oncology on Women's Cancer; March 9-12, 2013; Los Angeles, California.
75. Shahzad MM, Arevalo JM, Armaiz-Pena GN, et al. Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 2010;285:35462-35470.
76. Tarsitani L, De Santis V, Mistretta M, et al. Treatment with beta-blockers and incidence of post-traumatic stress disorder after cardiac surgery: a prospective observational study. J Cardiothorac Vasc Anesth 2012;26:265-269.
77. Hanke ML, Powell ND, Stiner LM, et al. Beta adrenergic blockade decreases the immunomodulatory effects of social disruption stress. Brain Behav Immun 2012;26:1150-1159.
78. Hyltander A, Daneryd P, Sandstrom R, et al. Beta-adrenoceptor activity and resting energy metabolism in weight losing cancer patients. Eur J Cancer 2000;36:330-334.